// App-Quantinova.ai

e12653 : Longterm survival benefit of neoadjuvant liposomal doxorubicin, docetaxel, and trastuzumab in HER2-overexpressing breast cancer: A retrospective and multicenter analysis.

Researchers

Presenter

  • Christine Brunner

Principal Investigators

  • Verena Wieser

  • Thomas Jaeger

  • Alois Lang

  • Herbert Stoger

  • Christoph Suppan

  • Georg Goebel

  • Afschin Soleiman

  • Daniel Egle

  • Christian Marth

  • Michael Hubalek

Medical Centers

  • Department og Gynecology and Obstetrics, Innsbruck, Austria

  • LKH Feldkirch, Feldkirch, Austria

  • Landeskrankenhaus Feldkirch, Feldkirch, Austria

  • Medical University Graz, Graz, Austria

  • Department of Internal Medicine, Medical University Graz, Graz, Austria

  • Department of Medical Statistics, Informatics and Health Oeconomics, Medical University Innsbruck, Innsbruck, Austria

  • Department og Gynecology and Obstetrics, Innsbruck, Austria

  • Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria

  • AGO-A and Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria

  • Innsbruck Medical University, Innsbruck, Austria

Locations

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab

  • Doxorubicin

  • Docetaxel

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved